Warning letter
Valeant Pharmacueticals International: warning letter of Nov 3, 2016
FDA warning letter 521798 · New York District Office
Key facts
| Reference number | 521798 |
|---|---|
| Company | Valeant Pharmacueticals International |
| Subject | CGMP/QSR/Medical Devices/Adulterated |
| Issue date | Nov 3, 2016 |
| Posted date | Nov 3, 2016 |
| Issuing office | New York District Office |
| Product type | Tobacco |
| CFR sections cited | 820 |
| Inspection city | Rochester |
| Inspection ZIP | 14609 |
| Inspection start date | Aug 23, 2016 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: